Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
July 22 2024 - 7:00AM
Business Wire
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical
company pioneering a new and differentiated class of therapeutics
based on its proprietary bicyclic peptide (Bicycle®) technology,
today announced the acceptance of four abstracts for poster
presentation at the European Society for Medical Oncology (ESMO)
Congress 2024, taking place September 13-17 in Barcelona.
Poster Presentation Details:
Title: BT8009 monotherapy in enfortumab vedotin-naïve
patients with metastatic urothelial carcinoma (mUC): Updated
results of Duravelo-1 Poster Session Title: Poster session
01 Date and Time: Saturday, Sept. 14, at 9-10 a.m. CEST
Presentation Number: 652P Speaker: Oscar Reig Torras,
M.D., Hospital Clinic de Barcelona
Title: Peripheral neuropathy following treatment with
Bicycle Toxin Conjugates® BT8009 or BT5528 monotherapy in patients
with advanced solid tumors Poster Session Title: Poster
session 01 Date and Time: Saturday, Sept. 14, at 9-10 a.m.
CEST Presentation Number: 654P Speaker: Bernard Doger
de Spéville, M.D., Ph.D., START Madrid-FJD and Hospital
Universitario Fundacion Jimenez Diaz
Title: EphA2-targeting Bicycle® Toxin Conjugate BT5528 in
patients with advanced solid tumors: A phase 1/2 study Poster
Session Title: Poster session 01 Date and Time:
Saturday, Sept.14, at 9-10 a.m. CEST Presentation Number:
647P Speaker: Elisa Fontana, M.D., Ph.D., Sarah Cannon
Research Institute UK
Title: Initial results from a phase 1/2 study of BT7480,
a novel Nectin-4/CD137 Bicycle Tumor-Targeted Immune Cell Agonist®,
in patients with advanced solid tumors Poster Session Title:
Poster session 01 Date and Time: Saturday, Sept.14, at 9-10
a.m. CEST Presentation Number: 650P Speaker: Kyriakos
P. Papadopoulos, M.D., START San Antonio
The posters will be made available in the Publications section
of bicycletherapeutics.com following the presentations.
About Bicycle Therapeutics Bicycle Therapeutics is a
clinical-stage pharmaceutical company developing a novel class of
medicines, referred to as Bicycle® molecules, for diseases that are
underserved by existing therapeutics. Bicycle molecules are fully
synthetic short peptides constrained with small molecule scaffolds
to form two loops that stabilize their structural geometry. This
constraint facilitates target binding with high affinity and
selectivity, making Bicycle molecules attractive candidates for
drug development. The company is evaluating zelenectide pevedotin
(formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting
Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule
targeting EphA2, a historically undruggable target; and BT7480, a
Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®)
targeting Nectin-4 and agonizing CD137, in company-sponsored
clinical trials. Additionally, the company is developing Bicycle®
Radio Conjugates (BRC™) for radiopharmaceutical use and, through
various partnerships, is exploring the use of Bicycle® technology
to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with
many key functions and members of its leadership team located in
Cambridge, Mass. For more information, visit
bicycletherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722899403/en/
Investors: Stephanie Yao SVP, Investor Relations and
Corporate Communications ir@bicycletx.com 857-523-8544
Media: Argot Partners Deborah Elson media@bicycletx.com
212-600-1902
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Aug 2023 to Aug 2024